Pharmalex Nordic ApS: Financial statements 2022
CVR: 37541540
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Pharmalex Nordic ApS (CVR 37541540) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,282,689 and a net result of DKK 1,404,916 compared with DKK 4,937,451 the year before. That is a decrease of 2.1% compared with the year before. Equity in the 2022 report amounted to DKK 34,541,299. The solvency ratio was 12.5%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 3,282,689
- Profit/Loss
- DKK 1,404,916
- Equity
- DKK 34,541,299
- Total Assets
- DKK 276,311,133
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 3.3M | 1.4M | 34.5M | 2 |
| 2021 | - | 3.4M | 4.9M | 33.1M | 2 |
| 2020 | - | 2.6M | 3.6M | 28.2M | 2 |
| 2019 | - | 2.4M | 2.4M | 24.6M | 2 |
| 2018 | - | 1.9M | 892K | 22.2M | 1 |
Official annual report
Keep an eye on Pharmalex Nordic ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Pharmalex Nordic ApS has published its annual report for 2021. Gross profit came to DKK 3,352,246, and the net result was DKK 4,937,451.
About Pharmalex Nordic ApS
Pharmalex Nordic ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Åsa Pihlblad and Christopher Gauglitz. The company is owned by AmerisourceBergen International B.V.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 3,533,803 and a net result of DKK 1,709,691 compared with DKK -88,447,652 the year before. Equity in the 2025 report amounted to DKK -45,957,544.